177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience

(2019) Arvind Sahu et al.   Journal of Oncology

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo

(2019) Brian H. White et al.   JOURNAL OF MEDICINAL CHEMISTRY

Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms

(2019) Eleftherios Chatzellis et al.   NEUROENDOCRINOLOGY

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan

(2019) Diane Reidy-Lagunes et al.   CLINICAL CANCER RESEARCH

Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours

(2019) George Papaxoinis et al.   NEUROENDOCRINOLOGY

Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms

(2019) Taymeyah Al‐Toubah et al.   ONCOLOGIST

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

(2018) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

(2018) Jingjing Zhang et al.   JOURNAL OF NUCLEAR MEDICINE

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

(2018) Martin H. Cherk et al.   CANCER IMAGING

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

(2018) Richard P. Baum et al.   Oncotarget

First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

(2018) Melissa Lynne Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

(2018) Jonathan R. Strosberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Acting Somatostatin Analog Therapy Differentially Alters68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions

(2017) Narjess Ayati et al.   JOURNAL OF NUCLEAR MEDICINE

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response

(2017) Dwight H. Owen et al.   Oncotarget

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

(2017) Bryan Oronsky et al.   NEOPLASIA

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC

(2015) Stefano Severi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models

(2015) S. U. Dalm et al.   JOURNAL OF NUCLEAR MEDICINE

PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization

(2014) L. Bodei et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

(2014) D. Wild et al.   JOURNAL OF NUCLEAR MEDICINE

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

(2014) Ebrahim S. Delpassand et al.   PANCREAS

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lutetium-labelled peptides for therapy of neuroendocrine tumours

(2012) B. L. R. Kam et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors

(2011) A. R. Haug et al.   JOURNAL OF NUCLEAR MEDICINE

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors

(2010) M. van Essen et al.   JOURNAL OF NUCLEAR MEDICINE

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY